Publications by authors named "Muhammad Faris Kairi"
J Immunother Cancer
June 2022
Article Synopsis
- TCR-engineered T cells targeting intracellular antigens like NY-ESO-1 show promise for treating solid tumors, but endogenous TCRs may hinder their effectiveness and cause self-reactivity.
- A phase I clinical trial tested a novel TCR-transduced T-cell product (TBI-1301) in patients with NY-ESO-1-expressing tumors, using siRNA to silence endogenous TCRs, with patients split into two dosing cohorts.
- Results indicated that while some patients exhibited tumor responses, early-onset cytokine release syndrome (CRS) occurred in several, and one experienced serious lung injury, highlighting the potential benefits and risks of TCR-T cell therapy.
